oral zolpidem prevents acute mountain sickness: a randomized double-blind placebo controlled study
Clicks: 117
ID: 254382
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
117 views
16 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #113 of 124 articles by views in frontiers in neurorobotics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 124 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective To study the prophylactic effect of zolpidem on acute mountain sickness (AMS) after acute high-altitude exposure. Methods A randomized double-blind placebo controlled trial was performed on the plateau. Forty subjects were randomly divided into zolpidem group and placebo group. The general clinical data, heart rate, blood pressure, oxygen saturation, the Pittsburgh Sleep Quality Index (PSQI) scores, AMS scores and physical fitness test of the both groups were collected and assessed on plain and plateau, respectively. Results The PSQI scores were obviously lower and the six-minute walk distance was significantly longer in zolpidem group than those in placebo group (P=0.047 and P=0.009, respectively) after acute high-altitude exposure. AMS incidence was significantly lower in zolpidem group than in placebo group at different time points (P=0.019, 0.014, 0.025 and 0.026, respectively), and the incidence of severe AMS was also significantly lower in zolpidem group than in placebo group at different time points (P=0.047, 0.044, 0.031 and 0.020, respectively). The symptoms of dizziness, weakness and fatigue were significantly lighter in zolpidem group than in placebo group after acute exposure to high-altitude exposure for 20 hours (P<0.05). No significant difference was found in the general physiological findings including, heart rate, blood pressure, oxygen saturation, physical capacity, and the power of hand grip between the 2 groups after acute high-altitude exposure (P>0.05). Conclusion Zolpidem may alleviate AMS symptoms and reduce the incidence of AMS, so it may be promising as a new choice for the prevention of AMS.
DOI: 10.11855/j.issn.0577-7402.2015.09.09
| Reference Key |
huang2015medicaloral
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Yong-tao HUANG;Jun QIN;Xu-bin GAO;Guo-zhu CHEN;Cheng-rong ZHENG;Jie YANG;Lan HUANG |
| Journal | frontiers in neurorobotics |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.